Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-03-18 | Reverse | 1:20 |
PDS Biotechnology, a clinical-stage biopharma founded in 2005, develops multifunctional cancer immunotherapies and vaccines, with lead candidates in Phase II trials and collaborations with NIH, Merck, HHS, and MSD.
An investigational T-cell activating immunotherapy designed to treat various HPV-positive cancers. As the company's lead candidate in a pivotal Phase 3 clinical trial, it represents PDS Biotechnology's most prominent and actively developed product.
In December 2025, PDS Biotechnology announced it had scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential accelerated approval pathway for its lead investigational immunotherapy, PDS0101, for the treatment of HPV16-positive head and neck cancer. Following this meeting, the company announced in January 2026 that it had gained alignment with the FDA on using Progression-Free Survival (PFS) as a primary endpoint in its Phase 3 VERSATILE-003 trial, a key step that could shorten the trial duration and lead to an earlier regulatory submission for accelerated approval.
In a significant strategic move, PDS Biotechnology actively engaged with the U.S. Food and Drug Administration (FDA) to amend the clinical trial design for its lead product candidate, PDS0101. The company is seeking to use Progression-Free Survival (PFS) as a primary endpoint to potentially shorten the timeline for regulatory approval for the treatment of HPV16-positive head and neck cancer, a move that could bring its key asset to market sooner.
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 OKUR | $2.25 | COMPARE |
 XLO | $8.78 | COMPARE |
 INMB | $1.84 | COMPARE |
 ANVS | $1.14 | COMPARE |
 TPST | $0.77 | COMPARE |
 RVPH | $0.50 | COMPARE |
